Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02531308 · ClinicalTrials.gov registry record · Phase 2
Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)
A Phase 2 study, sponsored by Rush University Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT02531308 is a Phase 2 study that was terminated before completion, run by Rush University Medical Center. The registered enrollment target is 5 participants.
The verdict
NCT02531308, a Phase 2 study, was terminated before completion, sponsored by Rush University Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
Evaluation of impact of metformin on 2 year progression-free survival (PFS) rate in subjects with previously untreated DLBCL when added to standard induction therapy. (R-CHOP)
Interventions
- DRUG Cyclophosphamide
- DRUG Doxorubicin
- DRUG Rituximab
- DRUG Metformin
- DRUG Vincristine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2015-07 |
| Est. Completion | 2016-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02531308
The ClinicalTrials.gov registry entry for NCT02531308 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT02531308 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02531308 about?
NCT02531308 is a clinical study titled "Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)". Evaluation of impact of metformin on 2 year progression-free survival (PFS) rate in subjects with previously untreated DLBCL when added to standard induction therapy. (R-CHOP)
What is the current status of trial NCT02531308?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2015-07. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02531308?
The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Rituximab (DRUG), Metformin (DRUG), Vincristine (DRUG).
Who is sponsoring clinical trial NCT02531308?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.